Anti-TCR [BMA031]

Absolute Antibody

Anti-TCR [BMA031]

9

This antibody reacts with surface receptors on all alpha-beta TCR bearing cells, but does not react with receptors on gamma-delta T cells. TCR-alphabeta is expressed by the majority of mature CD3+ T cells.

This antibody is recomended for detection of viable human alphabeta+ TCR lymphocyte. It is highly effective in modulating immune reactions and is capable of activating human T lymphocytes in vito (PMID: 3092794). Double immunofluorescence staining was used to ascertain that this antibody does not cross react with gammadelta+ TCR cells. FACS analysis confirmed that BMA031 did not react with gammadelta+ TCR cells. BMA031 successfully precipitates TCR alphabeta/CDR complex (PMID: 1704361). BMA031 in conjugation with triple drug induction treatment in kidney-transplanted patients showed no side effects and reduction in graft rejections (PMID: 2978369). A clinical phase II trial administered 50 mg of murine anti-human alpha/beta-TCR mAb (BMA 031) intravenously on the day of, as well as 2 and 4 days after, cadaveric donor renal transplantation in combination with a CsA/prednisone regimen. After a minimum of 30 months follow-up, the actual allograft survival rate was 87% in the BMA-treated group compared with 68% in the control cohort (PMID: 8009591).Humanized version of this antibody BMA 031-EUCIV3 is found to have 2.5 times less affinity than its murine parent, however the ability to cause antibody dependent cell-mediated cytolysis was significantly enhanced (PMID: 1836485).

Flow Cytometry, ImmunoFluorescence, ImmunoPrecipitation, Neutralisation/Blocking

Research Use Only

Monoclonal

BMA031

Mouse

IgG2b

Human

-20°C,2°C to 8°C

12352203